4 results match your criteria: "University Hospital Grosshadern-Munich[Affiliation]"
Anticancer Res
May 2009
Department of Urology, University Hospital Grosshadern - Munich, Marchioninistr. 15, D-81377 München, Germany.
In the past three decades many efforts have been undertaken to understand the mechanisms of tumor angiogenesis. The introduction of anti-angiogenic drugs in tumor therapy during the last few years necessitates the establishment of new techniques enabling molecular imaging of tumor vascular remodelling. The determination of tumor size as commonly used is not appropriate since the extended necrosis under anti-angiogenic therapy does not necessarily result in the reduction of tumor diameter.
View Article and Find Full Text PDFHistochem Cell Biol
September 2008
Department of Urology, University Hospital Grosshadern-Munich, Marchioninistr. 15, 81377 Munich, Germany.
Rete testis and epididymis are rare locations for primary tumors or metastasis. Assuming that this may be related to expression level of angiogenic inhibitors, we focused our study on the expression pattern of collagen 18/endostatin. In situ hybridization and immunohistochemistry for collagen 18 and endostatin were carried out on sections of human rete testis and epididymis as well as on epididymal adenoma and human testicular tissue with or without carcinoma in situ (CIS).
View Article and Find Full Text PDFEur Urol
May 2007
Department of Urology, University Hospital Grosshadern-Munich, Marchioninistrasse 15, D-81377 Munich, Germany.
Objectives: Varicocele, a dilatation of the pampiniform venous plexus, is considered to cause male infertility. The exact mechanism of varicocele development is not clarified yet. This study focused on the structure of varicocele veins, compared with normal spermatic veins, and its potential role in varicocele development.
View Article and Find Full Text PDFJ Heart Lung Transplant
November 2005
Department of Cardiac Surgery, Ludwig Maximilians University Hospital Grosshadern-Munich, Munich, Germany.
Background: In end-stage cardiomyopathy where concomitant chronic renal failure is a contraindication for cardiac transplantation (HTx), simultaneous heart and kidney transplantation (HKTx) may be the only feasible therapeutic option. Due to the increased donor shortage, the clinical outcome of combined HKTx patients on tacrolimus-based immunosuppression was assessed and compared with a group of HTx patients.
Methods: Three hundred forty-nine HTxs, including 13 (4%) combined HKTxs, were performed since 1995.